Articles On MGC Pharmaceuticals (ASX:MXC)

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 137-odd small cap health stocks, 61 were in positive territory over the last fortnight, 10 were flat and 66 saw their share prices fall. Code Name...

Medicinal cannabis company MGC Pharma (ASX:MXC) is staying busy during the pandemic, after getting ethics approval from a second hospital in Israel to run a phase II clinical trial on COVID-19 patients. The company also announced firm commi...

MGC Pharmaceuticals (ASX: MXC) is about to kick-off a phase II clinical trial evaluating a natural anti-infective drug on COVID-19 patients. Israel’s Nazareth Hospital Human Research Ethics Committee has given the go-ahead for MGC to procee...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Special Report: The upgraded deal is strong confirmation of MGC Pharma’s ability to execute on building a globally scalable cannabis distribution business. For seed-to-medicine cannabis company MGC Pharma (ASX:MXC), a strategic push into th...

There are ASX small caps addressing brain problems and stocks seeking to test cannabis for medicinal purposes and Impression Healthcare (ASX:IHL) is now doing both. This morning the company announced next quarter it would begin a clinical t...

As market watchers would know, cannabis stocks globally have had a wild ride over the last three years. The volatility is a natural by-product of any frontier market – full of stops and starts as companies try to build out their business mo...

Special Report: Prescription numbers surge as MGC Pharma finds its footing in the global cannabis marketplace. MGC Pharmaceuticals (ASX:MXC) has seen a 450 per cent increase in prescriptions during the December quarter as volumes hit 1890,...

The THC Global Group Ltd (ASX: THC) share price has just finished the week on a high. On Friday the medicinal cannabis company’s shares climbed as much as 4% higher before ending the day with a gain of 1.5% to 38 cents. Why did the THC Glo...

MGC Pharmaceuticals has a new agreement with Anden Bio Naturals to produce and supply white labelled cannabis-based medicinal products into Peru and Bolivia.

MGC Pharma (MXC) is set to enlarge its footprint in Latin America after entering a distribution agreement with Anden Bio Naturals The agreement will see Anden commercialise and distribute MGC Pharma’s cannabis based medicines in Peru and B...

Special Report: The deal with THC Global (ASX:THC) is evidence of the demand for MGC products in the broader medicinal cannabis market. Over the last 6 months, MGC Pharma (ASX:MXC) has established some good traction in the market with its...

MGC Pharmaceuticals has a new agreement in place with THC Global to produce and supply white labelled, pharmaceutical-grade cannabis-based medicinal products.

Hot on the heels of a new partnership with MGC Pharma (ASX: MXC) THC Global (ASX: THC) has received a licence to manufacture therapeutic goods at its state-of-the-art facility in Southport. The licence, known as a GMP Licence, is the fina...

THC Global (THC) has signed a supply agreement with MGC Pharmaceuticals (MXC) for its medicinal cannabis products THC’s Canndeo branded medicinal cannabis product range will be launching in Q1 2020 The agreement has a minimum term of 18...

Medicinal cannabis companies THC Global (ASX: THC) and Europe-based, Australian-listed MGC Pharma (ASX: MXC) have signed a new supply deal this morning. The agreement will see MGC Pharma provide THC Global with an "immediate" source of me...

The MGC Pharmaceuticals Ltd (ASX: MXC) share price is starting the week on a high. In morning trade the cannabis company’s shares are up 3% to 3.8%. They were up as much as 8% at one stage. Why is the MCG Pharma share price on a high? Inve...

The Cann Group Ltd (ASX: CAN) share price was on form again on Monday and recorded another strong gain. The medicinal cannabis company’s shares raced 13% higher to end the day at $1.07. This latest gain means that Cann Group’s shares have...

MGC Pharmaceuticals (MXC) has passed 2000 prescribed units of its cannabinoid medicines The increased prescriptions come from patients in Australia and the U.K. as well as Brazil and Ireland where the products were recently approved for...

The MGC Pharmaceuticals Ltd (ASX: MXC) share price has been a strong performer on Thursday. In morning trade the cannabis company’s shares have jumped 12% higher to 3.7 cents. Why is the MGC Pharma share price jumping higher today? Hot on...

MGC Pharmaceuticals has unveiled a new medicinal cannabis-based line for Australian and New Zealand markets to be called “Mercury Pharma”.

Special Report: MGC Pharma is launching a new line of medical cannabis products in order to target affordability and patient access. With affordability the key issue around access to cannabis medications, MGC Pharmaceuticals (ASX:MXC) is la...

MGC Pharmaceuticals (MXC) has launched its new “Mercury Pharma” medicinal cannabis brand The first Mercury Pharma product, MP100, has already received 2000 orders for January and February This is expected to bring in over $270,000 of reven...

The Cann Group Ltd (ASX: CAN) share price has returned from its trading halt and rocketed higher. In morning trade the cannabis company’s shares are up 25% to $1.26. Why is the Cann Group share price rocketing higher on Tuesday? Investors...

Marijuana is the hottest herb on the planet right now, but while investing in medical cannabis stocks could make you a fortune, it could also risk the house. After a flurry of activity on the ASX in 2017 as the sector kicked off following l...

There is a lot of optimism surrounding the outlook for the multi-billion-dollar global cannabis industry, which may not be still evident from the share prices but increasing number of nations are now introducing proper legal framework to ba...

MGC Pharmaceuticals will start phase two ‘b’ clinical trials for its “CogniCann” medicinal cannabis product aimed at dementia sufferers.

MGC Pharmaceuticals’ (MXC) first bulk shipment of CogniCann is en route to Australia and will arrive in the upcoming days The first shipment will allow the commencement of the phase IIb clinical trials in partnership with the University o...

Securities of MGC Pharmaceuticals Ltd (ASX: MXC) were removed from the restricted list of BNY Mellon’s Global Cannabis Security Policy. The move comes after the restriction was applied in October this year. BNY Mellon and its clearing hous...

MGC Pharmaceuticals has surpassed 1,800 prescriptions delivered for its medical cannabis-based products across the globe.

MGC Pharma (MXC) has now prescribed 1800 patients with its cannabis-based medicines This is an increase of more than 800 per cent since September The company has officially prescribed its first patients in Ireland after getting government...

MGC Pharmaceuticals Ltd (ASX: MXC) announced that it has reached more than 1,800 prescriptions of its standardised, affordable cannabinoid medicines, achieved from patients in Australia, the UK and with the latest additions of new patient s...

Money Talks is Stockhead’s regular drill down into what stocks investors are looking at right now. We’ll tap our extensive list of experts to see what’s hot, their top picks and what they’re looking out for. Today, we hear from Maxim Jacobs...

Emerging or early-stage companies offer new investment opportunities to investors, and higher returns are expected from start-ups due to their potential for growth. Investing in early-stage companies is risky; however, it offers the potenti...

A significant progress has been seen in Cannabis industry at a global scale, a sector that has witnessed traction and speculation at the same time. Once, a topic of taboo, cannabis is one of the most debated topics worldwide currently.  Can...

Special Report: Cannabis stock MGC Pharma will start its European tour in Big Pharma favourite Ireland after receiving a key approval for the EU market. Europe-based cannabis biopharma MGC Pharma (ASX:MXC) has received regulatory approval f...

In Australia, medical cannabis is regulated by the Australian Government through the Therapeutic Goods Administration (TGA) and the Office of Drug Control. The Therapeutic Goods Administration is developing guidelines for medicinal cannabis...

It has been a very disappointing day of trade for the S&P/ASX 200 index on Tuesday. In afternoon trade the benchmark index is down a sizeable 1.95% to 6,728.6 points. Four shares that have defied the market sell off today are listed be...

Cannabis space is evolving at a rapid pace with Cannabis legalisation changing the landscape across the globe. Cannabis industry is gaining investors attention despite economic pressures, market recklessness and strong competition. Cannabis...

The MGC Pharmaceuticals Ltd (ASX: MXC) share price has been a positive performer on Tuesday. In morning trade the cannabis company’s shares are up 3% to 3.5 cents. Why is the MGC Pharma share price charging higher? Investors have been buyi...

MGC Pharmaceuticals has joined Brazil’s leading merchant bank in its quest to conquer Latin America’s burgeoning medicinal cannabis market.

MGC Pharmaceuticals will carry out a clinical trial comparing the effectiveness of its medical cannabis products for the treatment of dementia and Alzheimer's.

The number of Australian patients being subscribed medicinal cannabis has risen a gigantic 1,191 per cent year-on-year, according to new data. Some 14,357 patients were approved medicinal cannabis, compared with 1,112 this time last year, a...

Pot stock Cann Group (ASX:CAN) has “moved into the commercialisation phase” — but it’s with imported products, as it continues to wait for approval for its own products from Australian regulators. Shares in Cann Group closed at $1.01 yester...

Cannabis Shares Valuing a cannabis company is becoming an increasingly difficult task. Lately, the cannabis shares have been taking a beat in the domestic markets, falling from their respective all-time highs. The table below provides you w...

There are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so — but less than 25 are anywhere close to their ultimate dream of bringing a drug successfully to market, a Stockhead analysis has found. Ta...

MGC Pharmaceuticals has surpassed 1,000 prescriptions delivered for its medical cannabis-based products, to more than 500 unique patients.

MGC Pharmaceuticals has surpassed 1,000 prescriptions delivered for its medical cannabis-based products, to more than 500 unique patients.

Cannabis is a high-growth industry with a rapidly changing environment. The companies discussed in this article are ASX-listed medicinal cannabis players. Medicinal cannabis companies are increasingly catching attraction from investors. As...

MGC Pharmaceuticals has surpassed 600 patients that have prescribed for or will be prescribing for its medical cannabis-based products.